Meyka Pro banner
Imagin Medical Inc.

Imagin Medical Inc. Fundamental Analysis (CNQ: IME.CN)

IME.CNCNQ
HealthcareMedical - Devices
$0.01
$0.00(0.00%)
Canadian Market opens in 6h 27m

Imagin Medical Inc. Fundamental Analysis (CNQ: IME.CN)

Imagin Medical Inc. (CNQ: IME.CN) shows moderate financial fundamentals with a PE ratio of -0.06, profit margin of 0.00%, and ROE of 20.04%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE20.04%
Cash Position26.89%
PEG Ratio0.00

Areas of Concern

Operating Margin0.00%
Current Ratio0.01
We analyze IME.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 62.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
62.1/100

We analyze IME.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

IME.CN struggles to generate sufficient returns from assets.

ROA > 10%
-1.84%

Valuation Score

Excellent

IME.CN trades at attractive valuation levels.

PE < 25
-0.06
PEG Ratio < 2
0.00

Growth Score

Weak

IME.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

IME.CN shows balanced financial health with some risks.

Debt/Equity < 1
-1.01
Current Ratio > 1
0.01

Profitability Score

Weak

IME.CN struggles to sustain strong margins.

ROE > 15%
20.04%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is IME.CN Expensive or Cheap?

P/E Ratio

IME.CN trades at -0.06 times earnings. This suggests potential undervaluation.

-0.06

PEG Ratio

When adjusting for growth, IME.CN's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Imagin Medical Inc. at -0.01 times its book value. This may indicate undervaluation.

-0.01

EV/EBITDA

Enterprise value stands at 3.90 times EBITDA. This is generally considered low.

3.90

How Well Does IME.CN Make Money?

Net Profit Margin

For every $100 in sales, Imagin Medical Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $20.04 in profit for every $100 of shareholder equity.

20.04%

ROA

Imagin Medical Inc. generates $-1.84 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.84%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.34 in free cash annually.

$-0.34

FCF Yield

IME.CN converts -20.98% of its market value into free cash.

-20.98%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.06

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.01

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.01

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.01

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.20

vs 25 benchmark

ROA

Return on assets percentage

-1.84

vs 25 benchmark

ROCE

Return on capital employed

0.26

vs 25 benchmark

How IME.CN Stacks Against Its Sector Peers

MetricIME.CN ValueSector AveragePerformance
P/E Ratio-0.0631.61 Better (Cheaper)
ROE20.04%541.00% Weak
Net Margin0.00%30180.00% Weak
Debt/Equity-1.010.54 Strong (Low Leverage)
Current Ratio0.015.70 Weak Liquidity
ROA-184.48%-8.00% (disorted) Weak

IME.CN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Imagin Medical Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ